Home
Contact Us
Site Map
 
 

Press Releases

August 2010
8/30/2010 Eisai Announces Extension of FDA Review of Drug Application
for Investigational Agent Eribulin Mesylate
8/24/2010 Eisai Announces Positive Phase III Trial Results for Perampanel
in Epilepsy
8/16/2010 Morphotek®, Inc Announces Initiation of a Phase I Study for MORAb-028,
an IgM-type Monoclonal Antibody, in Patients With Advanced Melanoma
8/6/2010 FDA Confirms September 16th Advisory Committee Meeting to Review Lorcaserin
for Obesity and Weight Management
 
July 2010
7/23/2010 Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval For New
Higher-Dose Aricept® (Donepezil HCl) 23 mg Tablet For the
Treatment of Moderate-to-Severe Alzheimer's Disease
Aricept available in 5 mg, 10 mg and 23 mg dose
7/19/2010 FDA Accepts BANZEL® Oral Suspension NDA for Review
7/14/2010 New England Journal of Medicine Publishes Results of Two-Year BLOOM TrialShowing Lorcaserin Caused Significant Weight Loss and
Improved Maintenance of Weight Loss
Lorcaserin Also Improved Values for Biomarkers That May be Predictors of
Future Cardiovascular Events
7/1/2010 Eisai Inc. Enters Marketing and Supply Agreement
with Arena Pharmaceuticals for Lorcaserin
A Potential Treatment for Obesity and Weight Management
 
June 2010
6/30/2010 Eisai Announces Results of Phase III Study of Dacogen® (Decitabine)
for Injection in Acute Myeloid Leukemia (AML)
Based on Preliminary Results Eisai Plans to Submit sNDA to FDA
6/28/2010 Eisai and Morphotek®, Inc. Announce Initiation of MORAb-022 Study in Europe
for the Treatment of Inflammatory Disease
 
View archived press releases

Printer Friendly Version

 
Go to Top